Microbion

Microbion is a private, clinical-stage biotech developing first-in-class therapeutics targeting biofilm-related and resistant infections. Its lead asset, pravibismane, is a broad-spectrum antimicrobial with a novel mechanism of action that halts microbial metabolism and disrupts biofilms, positioning it for serious unmet needs in diabetic foot ulcers and orthopedic infections. The company employs a site-specific delivery strategy to maximize local efficacy and safety, with two Phase 2 programs and backing from venture investors like Quark Venture.

Novel class of anti-infective compounds (pravibismane) that halt microbial cellular metabolism, uniquely prevent and eradicate biofilms, and exhibit anti-inflammatory/immunomodulatory effects. Employs site-specific delivery.

Competition includes other companies developing anti-biofilm agents (e.g., peptides, enzymes, small molecules) and new systemic antibiotics. Microbion's differentiation lies in pravibismane's unique mechanism, local delivery strategy, and dual anti-infective/anti-inflammatory action, targeting a specific niche of device-related and chronic wound infections.